INmune Bio (NASDAQ:INMB) Price Target Raised to $23.00

INmune Bio (NASDAQ:INMB) had its price objective boosted by Scotiabank from $22.00 to $23.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “sector outperform” rating on the stock. Scotiabank’s price objective would suggest a potential upside of 161.96% from the stock’s current price.

Other analysts have also issued reports about the company. Rodman & Renshaw assumed coverage on INmune Bio in a report on Tuesday, January 28th. They issued a “buy” rating and a $23.00 price objective for the company. Alliance Global Partners initiated coverage on INmune Bio in a research note on Monday, October 21st. They set a “buy” rating and a $20.00 price objective on the stock. Finally, RODMAN&RENSHAW raised shares of INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $21.00.

INmune Bio Trading Down 3.7 %

NASDAQ INMB traded down $0.34 during trading hours on Tuesday, reaching $8.78. 48,763 shares of the company traded hands, compared to its average volume of 479,630. The stock has a market capitalization of $194.65 million, a PE ratio of -4.03 and a beta of 1.87. INmune Bio has a 12 month low of $4.32 and a 12 month high of $14.74. The company has a 50 day moving average of $6.22 and a two-hundred day moving average of $6.08.

Institutional Investors Weigh In On INmune Bio

Several large investors have recently made changes to their positions in INMB. Financial Advocates Investment Management increased its stake in shares of INmune Bio by 14.8% during the fourth quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock valued at $72,000 after acquiring an additional 2,000 shares during the period. Rhumbline Advisers increased its position in shares of INmune Bio by 16.9% during the 4th quarter. Rhumbline Advisers now owns 16,744 shares of the company’s stock valued at $78,000 after purchasing an additional 2,424 shares during the period. Fermata Advisors LLC raised its stake in shares of INmune Bio by 10.0% in the 4th quarter. Fermata Advisors LLC now owns 46,997 shares of the company’s stock worth $219,000 after buying an additional 4,267 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of INmune Bio in the third quarter valued at $79,000. Finally, Westside Investment Management Inc. boosted its stake in INmune Bio by 26.2% during the fourth quarter. Westside Investment Management Inc. now owns 89,975 shares of the company’s stock valued at $420,000 after buying an additional 18,660 shares in the last quarter. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.